The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Study Finds Mirikizumab Superior to Secukinumab for Plaque Psoriasis

Study Finds Mirikizumab Superior to Secukinumab for Plaque Psoriasis

August 7, 2020 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Mirikizumab is a humanized, IgG4, monoclonal antibody that binds to the p19 subunit of IL-23. It’s currently in clinical trials to manage immune mediated diseases, such as Crohn’s disease, ulcerative colitis and psoriasis. The randomized, phase 2 OASIS-2 trial (N=1,465, NCT03535194) compared the safety and efficacy of subcutaneous mirikizumab with subcutaneous secukinumab and placebo in adults with moderate to severe plaque psoriasis.1

You Might Also Like
  • Mirikizumab Promising for Plaque Psoriasis
  • Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis
  • Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity
Explore This Issue
September 2020
Also By This Author
  • FDA Approves Risankizumab-rzaa for PsA

Endpoints for this multicenter, doubleblind, placebo-controlled study included the proportion of patients with a Static Physician’s Global Assessment (sPGA) of 0 or 1 who achieved at least a two-point improve ment and the proportion of patients who achieved at least a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90), compared with placebo, at week 16. Evaluated secondary endpoints at week 16 included the proportion of patients who achieved at least a 75–100% improvement from baseline in the PASI 75/100.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients were randomized in a 4:4:4:1 ratio to receive:

  • 250 mg of mirikizumab at weeks 0, 4, 8 and 12, followed by 250 mg of mirikizumab every eight weeks starting at week 16;
  • 250 mg of mirikizumab at weeks 0, 4, 8 and 12, followed by 125 mg of mirikizumab every eight weeks starting at week 16;
  • 300 mg of secukinumab at weeks 0, 1, 2, 3 and 4, followed by 300 mg secukinumab every four weeks starting at week 4; or
  • Placebo at weeks 0, 4, 8 and 12, followed by 250 mg of mirakizumab every four weeks starting at week 16 through 32, followed by mirikizumab every eight weeks thereafter.

Patients were followed for 52 weeks.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Results: Mirikizumab met all the primary endpoints and all the key secondary endpoints at week 16, showing superiority to placebo. It also demonstrated non-inferiority to secukinumab in key secondary endpoints at week 16 and demonstrated superiority in key secondary endpoints at week 52.

The most common adverse event in mirikizumab-treated patients was nasopharyngitis, occurring in at least 5% of patients up to week 16. During the combined induction and maintenance treatment periods (up to week 52), the most common adverse reactions were arthralgias, back pain, headache, nasopharyngitis and upper respiratory infections. The frequency of serious adverse events was comparable across all treatments.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Eli Lilly and Co. News release: Lilly’s mirikizumab superior to Cosentyx (secukinumab) in a phase 3 study for patients with moderate to severe plaque psoriasis. 2020 Jul 17.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: mirikizumab, plaque psoriasis, secukinumabIssue: September 2020

You Might Also Like:
  • Mirikizumab Promising for Plaque Psoriasis
  • Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis
  • Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity
  • Guselkumab Studied to Treat RA & Plaque Psoriasis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)